A Phase Ib-IIa, Open-label, Dose-Escalation Study of the Safety, Tolerability and Pharmacokinetics of Trastuzumab Emtansine, Paclitaxel and Pertuzumab Administered Intravenously to Patients With Her2-positive, Locally Advanced or Metastatic Breast Cancer

Trial Profile

A Phase Ib-IIa, Open-label, Dose-Escalation Study of the Safety, Tolerability and Pharmacokinetics of Trastuzumab Emtansine, Paclitaxel and Pertuzumab Administered Intravenously to Patients With Her2-positive, Locally Advanced or Metastatic Breast Cancer

Completed
Phase of Trial: Phase I/II

Latest Information Update: 29 Jun 2016

At a glance

  • Drugs Trastuzumab emtansine (Primary) ; Paclitaxel; Pertuzumab
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Genentech
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 17 May 2016 The treatment table has been amended to include 6 arms (for phase1b and IIa) with different regimens.
    • 14 Dec 2013 Results from the phase IIa part of the study (n=44) presented at the 36th Annual San Antonio Breast Cancer Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top